Citations (36)
Keep up to date with the latest research on this topic with citation updates for this article.
Articles from other publishers (36)
Peng Hong, Mengshuo Wu, Xingchuan Wei, Xuetao Xu, Panpan Wu, Lishe Gan, Rihui Wu, Jingwei Jin, Kun Zhang, Dongli Li, Min Chen, Wingleung Wong, Wenfeng Liu & Xi Zheng. (2024) Inhibitory effect of liriopesides B in combination with gemcitabine on human pancreatic cancer cells. Bioorganic Chemistry 142, pages 106937.
Crossref
Crossref
Liang Zhang, Kangjing Qi, Jie Xu, Yan Xing, Xuejian Wang, Ling Tong, Zengguo He, Wenfang Xu, Xiaoyang Li & Yuqi Jiang. (2023) Design, Synthesis, and Anti-Cancer Evaluation of Novel Cyclic Phosphate Prodrug of Gemcitabine. Journal of Medicinal Chemistry 66:6, pages 4150-4166.
Crossref
Crossref
Li Xu, Shengnan Tang, Huiquan Yang, Min Liang, Pengfei Ren, Dandan Wei, Jian He, Weiwei Kong, Peidang Liu & Tianzhu Zhang. (2022)
Sustained delivery of gemcitabine
via in situ
injectable mussel-inspired hydrogels for the local therapy of pancreatic cancer
. Journal of Materials Chemistry B 10:33, pages 6338-6350.
Crossref
Crossref
Hongtao Xu, Yan Li, James W. Paxton & Zimei Wu. (2021) Co-Delivery Using pH-Sensitive Liposomes to Pancreatic Cancer Cells: the Effects of Curcumin on Cellular Concentration and Pharmacokinetics of Gemcitabine. Pharmaceutical Research 38:7, pages 1209-1219.
Crossref
Crossref
Yun-Ze Xuan, Cheng-Ri Jin & Kang-Juan Yang. (2020) TGF-β downregulation overcomes gemcitabine resistance in oral squamous cell carcinoma. Cancer Biomarkers 29:2, pages 179-187.
Crossref
Crossref
Yilin Sun, Jiankun Wang & Kun Hao. (2020) A Pharmacokinetic and Pharmacodynamic Evaluation of the Anti-Hepatocellular Carcinoma Compound 4-N-Carbobenzoxy-gemcitabine (Cbz-dFdC). Molecules 25:9, pages 2218.
Crossref
Crossref
Iyad Darweesh Al-Kashef, Salman Mostafa Saadeh, Khalid Ibrahim Abed Almonem, Nasser Mohammed Abu Ghalwa & Hazem Mohammed Abu Shawish. (2020) Fabrication and evaluation of potentiometric sensors of an anticancer drug (Gemcitabine). European Journal of Chemistry 11:1, pages 21-29.
Crossref
Crossref
Hassan Tamam, Jinho Park, Hytham H. Gadalla, Andrea R. Masters, Jelan A. Abdel-Aleem, Sayed I. Abdelrahman, Aly A. Abdelrahman, L. Tiffany Lyle & Yoon Yeo. (2019) Development of Liposomal Gemcitabine with High Drug Loading Capacity. Molecular Pharmaceutics 16:7, pages 2858-2871.
Crossref
Crossref
Kun Shi, Bingxin Xue, Yanpeng Jia, Liping Yuan, Ruxia Han, Fan Yang, Jinrong Peng & Zhiyong Qian. (2019) Sustained co-delivery of gemcitabine and cis-platinum via biodegradable thermo-sensitive hydrogel for synergistic combination therapy of pancreatic cancer. Nano Research 12:6, pages 1389-1399.
Crossref
Crossref
Asmita Banstola, Fakhrossadat Emami, Jee-Heon Jeong & Simmyung Yook. (2018) Current Applications of Gold Nanoparticles for Medical Imaging and as Treatment Agents for Managing Pancreatic Cancer. Macromolecular Research 26:11, pages 955-964.
Crossref
Crossref
Yilin Sun, Le Zhen, Ying Peng, Jiankun Wang, Fei Fei, Lixiang Aa, Wenjiao Jiang, Xue Pei, Li Lu, Jie Liu, Guangji Wang & Kun Hao. (2018) Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2′, 2′-difluorodeoxyuridine in rat plasma by UFLC-MS/MS. Journal of Chromatography B 1084, pages 4-13.
Crossref
Crossref
Yuqi Jiang, Jinning Hou, Xiaoyang Li, Yongxue Huang, Xuejian Wang, Jingde Wu, Jian Zhang, Wenfang Xu & Yingjie Zhang. (2016) Discovery of a novel chimeric ubenimex–gemcitabine with potent oral antitumor activity. Bioorganic & Medicinal Chemistry 24:22, pages 5787-5795.
Crossref
Crossref
Hongtao Xu, James W. Paxton & Zimei Wu. (2016) Development of Long-Circulating pH-Sensitive Liposomes to Circumvent Gemcitabine Resistance in Pancreatic Cancer Cells. Pharmaceutical Research 33:7, pages 1628-1637.
Crossref
Crossref
Zhezhu Han, Seungha Lee, Suyeon Je, Chi-Yong Eom, Hye Jin Choi, Jae J. Song & Joo-Hang Kim. (2015) Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells. Apoptosis 21:3, pages 351-364.
Crossref
Crossref
Hongtao Xu, James W. Paxton & Zimei Wu. (2015) Enhanced pH-Responsiveness, Cellular Trafficking, Cytotoxicity and Long-circulation of PEGylated Liposomes with Post-insertion Technique Using Gemcitabine as a Model Drug. Pharmaceutical Research 32:7, pages 2428-2438.
Crossref
Crossref
Fu-Gui Ye, Chuan-Gui Song, Zhi-Gang Cao, Chen Xia, Dan-Na Chen, Li Chen, Shan Li, Feng Qiao, Hong Ling, Ling Yao, Xin Hu & Zhi-Ming Shao. (2015) Cytidine Deaminase Axis Modulated by miR-484 Differentially Regulates Cell Proliferation and Chemoresistance in Breast Cancer. Cancer Research 75:7, pages 1504-1515.
Crossref
Crossref
Dongxu Kang, Hye Jin Choi, Sujin Kang, So Young Kim, Yong-sic Hwang, Suyeon Je, Zhezhu Han, Joo-Hang Kim & Jae J. Song. (2015) Ratio of phosphorylated HSP27 to nonphosphorylated HSP27 biphasically acts as a determinant of cellular fate in gemcitabine-resistant pancreatic cancer cells. Cellular Signalling 27:4, pages 807-817.
Crossref
Crossref
Hongtao Xu, James Paxton, Joanne Lim, Yan Li, Wenli Zhang, Linda Duxfield & Zimei Wu. (2014) Development of High-Content Gemcitabine PEGylated Liposomes and Their Cytotoxicity on Drug-Resistant Pancreatic Tumour Cells. Pharmaceutical Research 31:10, pages 2583-2592.
Crossref
Crossref
Hongtao Xu, James Paxton, Joanne Lim, Yan Li & Zimei Wu. (2014) Development of a gradient high performance liquid chromatography assay for simultaneous analysis of hydrophilic gemcitabine and lipophilic curcumin using a central composite design and its application in liposome development. Journal of Pharmaceutical and Biomedical Analysis 98, pages 371-378.
Crossref
Crossref
Kei Tomihara, Hiroki Fuse, Wataru Heshiki, Rie Takei, Bin Zhang, Naoya Arai, Kenji Nakamori & Makoto Noguchi. (2014) Gemcitabine chemotherapy induces phenotypic alterations of tumor cells that facilitate antitumor T cell responses in a mouse model of oral cancer. Oral Oncology 50:5, pages 457-467.
Crossref
Crossref
Salaheldin S. Hamed, Robert M. Straubinger & William J. Jusko. (2013) Pharmacodynamic modeling of cell cycle and apoptotic effects of gemcitabine on pancreatic adenocarcinoma cells. Cancer Chemotherapy and Pharmacology 72:3, pages 553-563.
Crossref
Crossref
Enaksha R. Wickremsinhe, Lisa B. Lee, Chris A. Schmalz, John Torchia & Kenneth J. Ruterbories. (2013) High sensitive assay employing column switching chromatography to enable simultaneous quantification of an amide prodrug of gemcitabine (LY2334737), gemcitabine, and its metabolite dFdU in human plasma by LC–MS/MS. Journal of Chromatography B 932, pages 117-122.
Crossref
Crossref
Enaksha Wickremsinhe, Jingqi Bao, Richard Smith, Richard Burton, Shannon Dow & Everett Perkins. (2013) Preclinical Absorption, Distribution, Metabolism, and Excretion of an Oral Amide Prodrug of Gemcitabine Designed to Deliver Prolonged Systemic Exposure. Pharmaceutics 5:4, pages 261-276.
Crossref
Crossref
Tingting Weng, Harry Karmouty‐Quintana, Luis J. Garcia‐Morales, Jose G. Molina, Mesias Pedroza, Raquel R. Bunge, Brian A. Bruckner, Matthias Loebe, Harish Seethamraju & Michael R. Blackburn. (2013) Hypoxia‐induced deoxycytidine kinase expression contributes to apoptosis in chronic lung disease. The FASEB Journal 27:5, pages 2013-2026.
Crossref
Crossref
Gee Young Lee, Wei Ping Qian, Liya Wang, Yongqiang Andrew Wang, Charles A. Staley, Minati Satpathy, Shuming Nie, Hui Mao & Lily Yang. (2013) Theranostic Nanoparticles with Controlled Release of Gemcitabine for Targeted Therapy and MRI of Pancreatic Cancer. ACS Nano 7:3, pages 2078-2089.
Crossref
Crossref
Foong Ying Wong, Natalia Liem, Chen Xie, Fui Leng Yan, Wing Cheong Wong, Lingzhi Wang & Wei-Peng Yong. (2012) Combination Therapy with Gossypol Reveals Synergism against Gemcitabine Resistance in Cancer Cells with High BCL-2 Expression. PLoS ONE 7:12, pages e50786.
Crossref
Crossref
XI ZHENG, XIAO-XING CUI, ZHI GAO, MICHAEL VERANO, MOU-TUAN HUANG, YUE LIU, ARNOLD B. RABSON & ALLAN H. CONNEY. (2012) Effects of 12-O-tetradecanoylphorbol-13-acetate in combination with gemcitabine on Panc-1 pancreatic cancer cells cultured in vitro or Panc-1 tumors grown in immunodeficient mice. International Journal of Oncology 41:6, pages 2269-2275.
Crossref
Crossref
Hironori Motoshige, Kyohei Oyama, Kiyoshi Takahashi & Koichi Sakurai. (2012) Involvement of Phosphatidylinositol 3-Kinase/Akt Pathway in Gemcitabine-Induced Apoptosis-Like Cell Death in Insulinoma Cell Line INS-1. Biological and Pharmaceutical Bulletin 35:11, pages 1932-1940.
Crossref
Crossref
Ramesh K. Ramanathan, James Abbruzzese, Tomislav Dragovich, Lynn Kirkpatrick, Jose M. Guillen, Amanda F. Baker, Linda A. Pestano, Sylvan Green & Daniel D. Von Hoff. (2010) A randomized phase II study of PX-12, an inhibitor of thioredoxin in patients with advanced cancer of the pancreas following progression after a gemcitabine-containing combination. Cancer Chemotherapy and Pharmacology 67:3, pages 503-509.
Crossref
Crossref
Enaksha R. Wickremsinhe, Barry S. Lutzke, Barry R. Jones, Gary A. Schultz, Angela B. Freeman, Susan E. Pratt, Angela M. Bones & Bradley L. Ackermann. (2010) Quantification of Gemcitabine Incorporation into Human DNA by LC/MS/MS as a Surrogate Measure for Target Engagement. Analytical Chemistry 82:15, pages 6576-6583.
Crossref
Crossref
H. Oettle, U. Pelzer, J. Stieler & H. Riess. (2010) Adjuvante und palliative Therapie des PankreaskarzinomsAdjuvant and palliative therapy of pancreatic cancer. Der Onkologe 16:6, pages 595-603.
Crossref
Crossref
Barbara Pili, L. Harivardhan Reddy, Claudie Bourgaux, Sinda Lepêtre-Mouelhi, Didier Desmaële & Patrick Couvreur. (2010) Liposomal squalenoyl-gemcitabine: formulation, characterization and anticancer activity evaluation. Nanoscale 2:8, pages 1521.
Crossref
Crossref
Takahisa Furuta. (2009) Pharmacogenomics in chemotherapy for GI tract cancer. Journal of Gastroenterology 44:10, pages 1016-1025.
Crossref
Crossref
Sevtap Savas & Geoffrey Liu. (2009) Genetic variations as cancer prognostic markers: review and update. Human Mutation 30:10, pages 1369-1377.
Crossref
Crossref
Mats Ljungman. (2009) Targeting the DNA Damage Response in Cancer. Chemical Reviews 109:7, pages 2929-2950.
Crossref
Crossref
Madlaina Breuleux & Heidi A. Lane. 2010. mTOR Pathway and mTOR Inhibitors in Cancer Therapy. mTOR Pathway and mTOR Inhibitors in Cancer Therapy
149
178
.